Evidence map›Paper›PMID 28255252›Full record

ReviewInternational journal of general medicine2017

Hepatitis C treatment: where are we now?

Nicholas J Burstow, Zameer Mohamed, Asmaa I Gomaa, Mark W Sonderup, Nicola A Cook, Imam Waked, C Wendy Spearman, Simon D Taylor-Robinson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of general medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Outcomes of Low Barrier Hepatitis C Treatment in High Risk Populations From Primary Care.Journal of community hospital internal medicine perspectives · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicholas J BurstowLiver Unit, Department of Surgery and Cancer, Imperial College London, London, UK.
Zameer MohamedLiver Unit, Department of Surgery and Cancer, Imperial College London, London, UK.
Asmaa I GomaaNational Liver Institute, Menoufiya University, Shbeen El Kom, Egypt.
Mark W SonderupDivision of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, Republic of South Africa.
Nicola A CookLiver Unit, Department of Surgery and Cancer, Imperial College London, London, UK.
Imam WakedNational Liver Institute, Menoufiya University, Shbeen El Kom, Egypt.
C Wendy SpearmanDivision of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, Republic of South Africa.
Simon D Taylor-RobinsonLiver Unit, Department of Surgery and Cancer, Imperial College London, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Chronic hepatitis C infection affects millions of people worldwide and confers significant morbidity and mortality. Effective treatment is needed to prevent disease progression and associated complications. Previous treatment options were limited to interferon and ribavirin (RBV) regimens, which gave low cure rates and were associated with unpleasant side effects. The era of direct-acting antiviral (DAA) therapies began with the development of first-generation NS3/4A protease inhibitors in 2011. They vastly improved outcomes for patients, particularly those with genotype 1 infection, the most prevalent genotype globally. Since then, a multitude of DAAs have been licensed for use, and outcomes for patients have improved further, with fewer side effects and cure rates approaching 100%. Recent regimens are interferon-free, and in many cases, RBV-free, and involve a combination of DAA agents. This review summarizes the treatment options currently available and discusses potential barriers that may delay the global eradication of hepatitis C.

Indexed as

directly acting antiviralshepatitis Chepatitis C eradicationinterferon-free regimensprotease inhibitorsribavirin-free regimens

Identifiers

PMID28255252
PMCPMC5322849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.